GE HealthCare Technologies Inc. (GEHC) Aandelenanalyse

Bedrijfsoverzicht

GE HealthCare Technologies Inc. is a leading entity within the healthcare sector, specifically specializing in the medical devices industry through the development, manufacture, and marketing of diagnostic and monitoring solutions for patients globally. The company operates across the United States, Canada, and international markets, offering a comprehensive suite of products, services, and complementary digital solutions designed to support clinical workflows in diagnosis, treatment, and patient monitoring. Operating on a significant scale, the enterprise commands a market capitalization of $33.39B while generating annual revenue of $20.63B and employing approximately 54,000 individuals worldwide. These financial dimensions, particularly the substantial market cap relative to its revenue base, indicate that the company is a major market player with deep market penetration and significant operational footprint within the global medical technology landscape.

Financiële gezondheid

The company reported a trailing twelve-month revenue of $20.63B and net income of $2.08B, with an EBITDA figure of $3.64B, revealing a cost structure where non-cash expenses and taxes, interest, and depreciation account for a significant portion of gross revenue before arriving at the bottom line. While the free cash flow stands at $1.69B, this metric demonstrates the company's ability to generate cash beyond its operational needs after capital expenditures, providing substantial financial flexibility for reinvestment or debt servicing. The gross margin is recorded at 40.0%, which reflects the pricing power and efficiency of the manufacturing and supply chain operations before overhead costs are applied. The operating margin of 15.7% and profit margin of 10.1% further illustrate the impact of operating expenses and taxation, showing that roughly 10.1% of every dollar of revenue translates to actual net profit. On the balance sheet, the company holds $4.49B in cash against $10.46B in debt, resulting in a debt-to-equity ratio of 98.72, which suggests a leveraged capital structure where long-term obligations are substantial relative to shareholders' equity. Liquidity is maintained with a current ratio of 1.37, indicating that current assets are 1.37 times greater than current liabilities, providing a comfortable buffer for meeting short-term obligations. Management effectiveness is highlighted by a return on equity of 22.4% and a return on assets of 5.5%, demonstrating that the company generates high returns on the capital invested by shareholders relative to the total asset base utilized to generate those earnings.

Waarderingsbeoordeling

The trailing twelve-month P/E ratio is 16.08, while the forward P/E is 13.18, implying that the market expects earnings growth in the future that would justify a lower multiple compared to historical performance. The price-to-book ratio stands at 3.21, indicating that the stock trades at a significant premium over its book value, which suggests the market values the company's intangible assets, brand, and future growth prospects highly. Alternative valuation metrics such as the price-to-sales ratio of 1.62 and an EV/EBITDA of 10.86 provide additional context, suggesting the company is valued moderately relative to its sales volume and enterprise earnings before interest, taxes, depreciation, and amortization. Regarding price volatility, the stock has traded between a 52-week low of $59.95 and a 52-week high of $89.77, meaning the current valuation sits within this established trading range and reflects recent market sentiment. The beta value of 1.30 indicates that the stock is more volatile than the broader market, moving with greater intensity than the general index, which is characteristic of the cyclical nature of the medical device sector.

Growth & Income

Revenue growth for the trailing twelve months stands at 7.1%, whereas earnings growth is recorded at -17.7%, indicating that earnings are currently contracting at a much faster rate than revenue expansion, which often signals rising costs or margin compression despite top-line growth. As a dividend payer, the company offers a dividend yield of 0.2% with a payout ratio of 3.1%, a level that is mathematically sustainable given the current earnings but reflects a conservative approach to returning capital to shareholders. The minimal payout ratio suggests that the company prioritizes retaining earnings for operational scaling and research rather than maximizing immediate dividend returns. Overall, the company presents a profile characterized by steady revenue expansion paired with a temporary earnings contraction, supported by a conservative dividend policy and a capital structure that balances liquidity with long-term leverage.